P82 Identification in osteoarthritic chondrocytes of proteins binding to the novel regulatory site AGRE in the human MMP-13 proximal promoter  by unknown
Osteoarthritis and Cartilage Vol. 13, Supplement A $49 
these poABs to compete for the binding of fluid phase neoepitope 
fragments with solid phase ovalbumin linked synthetic peptides. 
The solid phase complex is detected with peroxidase conjugated 
anti-rabbit IgG. These competitive ELISAs have nM sensitivity as 
determined by spike recovery of synthetic peptide in the assay 
buffer. Neoepitope specific ELISA assays will enable the quanti- 
tative evaluation of neoepitope containing aggrecan fragments in 
response to disease progression and therapeutic intervention. 
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Aim: To measure the levels of aggrecanase (ADAMTS)- 
generated aggrecan AGG-C1 neoepitope (G1-TEGE 373) in bio- 
logical fluids from a preclinical model of osteoarthritis (OA), and 
determine its utility as a correlative biomarker for disease pro- 
gression. 
Methods: A preclinical model of OA was propagated following 
anterior cruciate ligament ransection (ACLT) in rabbit hind-limbs, 
and biological fluid samples (i.e. serum, synovial fluid, urine) were 
collected at various time points post-surgery. Samples from age- 
matched control (unoperated) animals were similarly harvested. 
Monoclonal antibody AGG-C1 (which specifically recognizes the 
aggrecanase-generated catabolic neoepitope ... TEGE 373) was 
utilized in a competitive ELISA format to assay biological fluids. 
Results: AGG-C1 neoepitope was readily detectable in synovial 
fluid and serum samples, wherein its levels were elevated longi- 
tudinally following ACLT surgery. 
Conclusions: During the course of degenerative joint diseases 
such as OA, ADAMTS (aggrecanase)-mediated aggrecanoly- 
sis contributes ignificantly to cartilage proteoglycan depletion, 
and ultimate tissue destruction. Specifically, cleavage of the 
aggrecanase-susceptible E373-A 374 bond within the interglobular 
domain causes the detrimental loss of sGAG-rich aggrecan frag- 
ments, thereby compromising the biomechanical competence of 
the articular cartilage. Concordantly, aggrecanase-generated G1
domains (G1-TEGE 373) are also released from cartilage into the 
synovial fluid. In the present study, we have demonstrated the 
utility of neoepitope-specific monoclonal antibody AGG-C1 (anti- 
TEGE 373) in a preclinical biomarker assay for OA progression, us- 
ing accessible biological fluids such as peripheral blood (serum), 
wherein the AGG-C1 neoepitope persists. 
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Aim: ADAMTS-4 and ADAMTS-5 are known to cleave aggre- 
can, the major articular cartilage proteoglycan, at various sites 
along the molecule. This results in the release of aggrecan frag- 
ments into synovial fluid which contain the aggrecan neoepi- 
tope NITEGE and the glycosaminoglycan, chondroitin sulphate 
(CS). We have used this information to develop two pharmaco- 
dynamic assays to test ADAMTS-4/5 inhibitors in vivo. Aggrecan 
degradation is induced by the intra-articular injection of recom- 
binant ADAMTS-4 or ADAMTS-5 followed by detection of aggre- 
can catabolism with either a direct ELISA based on an antibody 
to a CS epitope or a sandwich ELISA utilizing antibodies to both 
the NITEGE neoepitope and the HABR (aggrecan hyaluronic acid 
binding region). 
Method: Male Lewis rats are anaesthetized and injected intra- 
articularly with varying concentrations of either recombinant 
ADAMTS-4 or ADAMTS-5 dissolved in 50ul of buffer. The con- 
tralateral knee is injected with buffer alone as a control. One 
hour after injection of enzyme the knees are lavaged with 200ul 
of saline and the synovial lavage assayed for CS and NITEGE 
content. Lavage fluid is measured for CS by an ELISA which 
uses mouse monoclonal antibody CS56 that recognizes CS and 
for NITEGE with a sandwich ELISA which uses antibodies to 
hyaluronic binding region (HABR) of aggrecan and the NITEGE 
neoepitope. MMP-13 (2.5ug per knee) was used as a specificity 
control for the NITEGE-HABR ELISA. 
To test ADAMTS-4/5 inhibitory activity of com pounds in this assay 
we used two broad-spectrum MMP inhibitors (Marimastat, British 
Biotech and Ro130830, Roche Bioscience) that also have some 
activity against ADAMTS-4 and ADAMTS-5: Marimastat IC50 22 
nM and 80 nM; Ro 130830 Marimastat IC50 200 nM and 56 nM 
respectively. IC50's were determined from an alpha screen assay 
for aggrecanases using a synthetic 43mer peptide as substrate. 
The compounds were dosed at 50mg/kg po one hour before in- 
jection of enzyme. Plasma was taken one hour after enzyme in- 
jection and assayed for MMP activity to confirm the presence of 
compound. 
Results: Both ADAMTS-4 and ADAMTS-5 at 10ug per knee were 
able to degrade rat knee cartilage aggrecan in vivo as measured 
by the release of CS and the NITEGE neoepitope. Levels of CS 
and NITEGE in synovial lavage were at least 10 fold higher than 
those seen with buffer alone. No NITEGE fragments were de- 
tected in MMP-13 injected knees. 
Marimastat was the most potent compound at inhibiting 
ADAMTS-4 (CS ELISA 60% and NITEGE-HABR ELISA 70%) 
and Ro130830 most potent for ADAMTS-5 (CS ELISA 60% and 
NITEGE-HABR ELISA 60%). The plasma assay for MMP activity 
showed complete inhibition of enzymatic activity. 
Discussion: Both ADAMTS-4 and ADAMTS-5 were able to de- 
grade aggrecan after intra-articular injection as measured by 
chondrotin sulphate and NITEGE-HABR ELISAs. This degrada- 
tion of aggrecan can be inhibited by reference compounds con- 
firming we have a pharmacodynamic assay for testing potential 
ADAMTS-4/5 inhibitors in vivo. 
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Aim of Study: The human MMP-13 plays a major role in normal 
cartilage remodeling and osteoarthritic (OA) processes. We pre- 
viously identified the regulatory site AGRE (GAAAA GAAAAAG) 
in the proximal promoter of this gene. Electrophoretic mobility 
shift assays (EMSA) done with nuclear extracts from OA chon- 
drocytes showed the presence of two AGRE-protein binding com- 
plexes, which depended on the pathophysiological state of the 
cells. In this study, we further investigated whether each AGRE 
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half site is active individually or if the site functions as a whole 
unit. Moreover, we identified AGRE-binding proteins according to 
OA human subgroups. 
Methods: Promoter activity was determined by transient rans- 
fection into human OA chondrocytes. AGRE-binding proteins 
were extracted from the EMSA complexes or following passage 
through magnetic beads covalently linked with AGRE-containing 
oligonucleotides and separated by 2-D gel electrophoresis. Pro- 
teins were identified by mass spectroscopy. Two OA subgroups 
have previously been identified and named L-OA chondrocytes 
(low MMP-13 basal levels and high IL-11~-inducibility) and H- 
OA chondrocytes (high MMP-13 basal levels and low IL-11~- 
inducibility). 
Results: i) Mutation(s) in each half site individually reduced the 
promoter activity, indicating that the intact AGRE site is required 
for complete MMP-13 expression, ii) The protein DDB1 (damage 
specific DNA binding protein 1) was identified in the L-OA chon- 
drocyte subgroup, iii) The mutation of the first half of the AGRE 
site (GTGCTGAAAAAG) reproduced the EMSA pattern seen in 
the H-OA chondrocyte subgroup. Mass spectroscopy identified 
p130 TM as one of the proteins in this complex, p130 TM is a dock- 
ing protein known to bind the transcription factor NMP4/CIZ that 
binds the consensus site G/CAAAAA. NMP4 has previously been 
reported to up-regulate some MMP expression. 
Conclusion: Altogether, these data suggest that in H-OA chon- 
drocytes, DDB1 levels may be reduced with or without a con- 
comitant up-regulation of p130cas/NMP4 expression and dis- 
placement of DDB1. These data indicate that the complex 
p130cas/NMP4, by regulating MMP-13 expression, may transform 
the chondrocytes from L-OA into H-OA. 
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Aim of Study: Osteoarthritis (OA) is the most common rheuma- 
tologic disease involving alterations in both proteoglycans and the 
collagen network of cartilage. One of the proteoglycan families is 
the small leucine rich proteoglycans (SLRPs). SLRPs are char- 
acterized by their association with collagen fibrils. Opticin is a 
glycoprotein and class III member of the SLRP family, which was 
initially identified associated with the collagen fibrils of the vitre- 
ous humor of the eye. Because collagen alteration in OA carti- 
lage induces an irreversible degradative process, we first investi- 
gated whether opticin is present in human articular tissues, and 
whether its integrity is maintained in OA cartilage. Furthermore, 
we studied the ability of the key metalloprotease involved in car- 
tilage pathology, MMP-13, to cleave human cartilage opticin. 
Methods: Opticin gene expression was investigated in normal 
and OA human chondrocytes, osteoblasts and synoviocytes by 
real-time PCR. Opticin protein production was determined in nor- 
mal and OA cartilage by immunomorphometry using a specific 
antibody. Opticin was isolated from human cartilage using guani- 
dinium chloride (4 M) extraction, and examined by Western blot- 
ting. Human MMP-13 proteolytic activity on opticin was analysed 
on cartilage extracts incubated for 0-16 hours. 
Results: Opticin was expressed in human chondrocytes, os- 
teoblasts and synoviocytes, and the protein identified in cartilage. 
At the protein level, comparison between normal and OA showed 
that OA cartilage has a slightly higher level of opticin positive 
stained chondrocytes than normal. However, in contrast with OA, 
normal cartilage demonstrated a high level of matrix staining in 
the superficial ayers of the tissue, suggesting that in the OA car- 
tilage matrix, opticin is degraded. Data also showed that cartilage 
opticin could be cleaved by MMP-13 after 16 hours of incubation. 
Conclusion: We demonstrated, for the first time, the expression 
and protein production of opticin in human articular tissues. Our 
data also showed that opticin in OA cartilage is degraded in a pro- 
cess that could be mediated by MMP-13. As SLRPs have been 
reported to regulate collagen fibril diameter and spacing, our data 
suggest that in OA cartilage, the digestion of opticin by MMP- 
13 may result in functional failure of this molecule, consequently 
leading to loss of the collagen fibril properties, predisposing the 
tissue to degeneration particularly at the articular surface. 
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Aim of Study: Bone morphogenic proteins (BMPs) are factors 
that play essential roles during adult bone remodeling and re- 
pair as well as during cartilage formation and maintenance. BMP 
activities are modulated by proteins known as BMP antagonists 
that prevent BMPs from binding to their specific receptors. In this 
study, we investigated the distribution and level of the BMP an- 
tagonist, chordin, in normal and osteoarthritic (OA) cartilage and 
synovial membrane, and the regulation of its expression in chon- 
drocytes and synovial fibroblasts following treatment with inflam- 
matory (IL-11~, TNF-~, IFN-~/) and growth (BMP-2, TGF-I~I, Activin 
A, EGF, bFGF, and PDGF-BB) factors. 
Methods: Localization of chordin in cartilage and synovial mem- 
brane as well as protein levels was performed by immunohisto- 
morphometric analysis on cartilage explants. Gene expression 
was determined using real-time PCR on human chondrocytes 
and synovial fibroblasts. 
Results: In normal cartilage, chordin was found at low levels 
(7.64-1.3% of positive cells) mainly at the very superficial ayers. 
In OA, chordin was also found at the superficial layers (8.94-1.1 %) 
but at a significantly higher level (24.74-1.5%, p<0.0001) in the 
middle and deep layers of the cartilage. Interestingly, chordin also 
demonstrated a differential regulation between normal and OA 
chondrocytes. In contrast to normal cells, chordin was markedly 
(p<0.01) down-regulated in OA chondrocytes by all the growth 
factors tested. IFN-~/ significantly (p<0.0002) stimulated its ex- 
pression in normal, but did not affect chordin in OA chondrocytes. 
However, both cell types were not affected by IL-11~ and TNF-~. 
Protein levels showed patterns similar to those of the mRNAs. 
The distribution and regulation of chordin was similar in normal 
and OA synovial membranes/fibroblasts. 
Conclusion: The increased level of chordin in OA cartilage as 
well as its location and its differential regulation between normal 
and OA chondrocytes uggest a role of this BMP antagonist in the 
OA process. Chordin may reduce the capacity of BMPs to induce 
OA cartilage repair, therefore favoring this tissue catabolism. The 
lack of effect by the inflammatory factors IL-11~ and TNF-~ indi- 
cates that inflammatory processes do not trigger chordin expres- 
sion. 
